PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Pfizer Inc. delivered a 17% total return since early November, but fundamentals lag and valuation isn’t compelling. Read more on PFE stock here.

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

It might be a good idea for short-term investors to avoid this Zacks Rank #5 (Strong Sell) stock for now. However, long-term investors may continue to hold the stock in their portfolio as Pfizer ...

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion. PFE is ...

I last covered Pfizer Inc. (PFE) stock on 8/6 with an article titled “Pfizer Q2: Dividends Speak Louder Than EPS”. The article was triggered by the company’s earnings report (ER) for Q2 2025 and rated ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price ...